Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 603.43% and currently trading at $930.00.
The company has been around since 1876 and the stock didn’t go public until 1952 but in the last 4 years, Eli Lilly went from a $100 billion market capitalization to $740 billion today, which also makes it a potential stock split stock.
However, as investors, we care about the stock price years down the line and what Eli Lilly will do in the next 3 to 5 years and beyond.
That is why 24/7 Wall Street looks at projected revenue and net income to give you our best estimate of future stock prices from 2025 to 2030.
Other “experts” look at past growth rates and assign future stock prices to those past numbers. However, we will walk you through our assumptions and give you the key drivers we see propelling Eli Lilly’s stock in the future.
Recent Eli Lilly Stock Updates and News
10/14/2024
Eli Lilly is expanding its Gateway Labs program to the United Kingdom, marking the first European location for the incubator program.
10/10/20024
Eli Lilly is taking legal action against compounding pharmacies that were temporarily allowed to produce generic versions of its weight loss drugs.
10/9/2024
Eli Lilly has entered into three agreements with Insitro, a machine-learning drug development company. The two will collaborate on new medicines for metabolic diseases.
10/8/2024
Eli Lilly has partnered with Qinotto, a company that is working on new ways to deliver large medicine molecules to the brain. The partnership will work to create new kinds of antibodies that can be used to transport medicines into the brain.
10/7/2024
Eli Lilly has received a positive analyst rating from Deutsche Bank. The analyst maintained a “Buy” rating for the company’s stock and set a price target of $1,025. This positive outlook is largely due to the resolution of a supply shortage for Tirzepatide.
10/4/2024
The Food and Drug Administration (FDA) has officially removed Eli Lilly’s Mounjaro and Zepbound from its shortage list.
10/2/2024
Today Eli Lilly announced plans for the Lilly Medicine Foundry. The company is investing $4.5 billion into the new center, located in Lebanon, Indiana, which will be home to drug development and advanced manufacturing.
10/1/2024
Eli Lilly is exploring the possibility of expanding its weight-loss drugs Mounjaro and Zepbound beyond just obese patients. The company is considering testing these medications on people who aren’t overweight but are at risk of gaining weight. CEO Dave Ricks theorizes that these medications might be beneficial for people who are at risk of developing diabetes, vascular dementia, or stroke, even if they’re not overweight.
9/30/2024
J.P. Morgan’s forecast for Eli Lilly estimates the company’s third quarter sales at $11.8 billion, driven by strong growth in U.S. GLP-1 sales and the international expansion of Mounjaro. While this forecast is slightly below consensus estimates, J.P. Morgan also estimates a significant increase in Mounjaro and Zepbound sales in Q4.
9/27/2024
Eli Lilly’s stock has seen a slight decline of 2.57% over the past month. Investors are keenly focused on the company’s upcoming earnings report. Eli Lilly is anticipated to report a substantial increase in earnings per share, a staggering 4,430% compared to the previous year.
Eli Lilly’s Recent Stock Success
How did Eli Lilly’s stock price soar so much in the past few years? Let’s take a look at the numbers:
| Share Price | Revenues* | Net Income* | |
| 2016 | $80.36 | $21.22 | $2.74 |
| 2017 | $77.55 | $19.94 | ($0.21) |
| 2018 | $122.13 | $21.49 | $3.23 |
| 2019 | $140.83 | $22.32 | $8.32 |
| 2020 | $206.46 | $24.54 | $6.19 |
| 2021 | $238.31 | $28.32 | $5.58 |
| 2022 | 329.07 | $28.54 | $6.25 |
| 2023 | $745.91 | $34.12 | $5.24 |
*Revenue and Net Income in Billions
Since 2016, Eli Lilly’s revenue grew by 60% but income grew by 91%. Typically you wouldn’t expect a company growing at its top line by 7% annually to see an 828% increase in share price, however, investor sentiment for the next line of drugs front ran the stock price.
For example, in 2016 Eli Lilly was trading 13 times the trailing 12 months earnings and the market has increased its valuation each year and currently trades at a 125 times earnings multiple.
This raises the valid question, is Eli Lilly overvalued or will future revenues make up for the expensive valuation?
3 Key Drivers of Eli Lilly Stock
- Innovated Drug Pipeline: The current drug pipeline is loaded with several very high-potential drugs in development. Mounjaro, Zepbound, and Jardiance in the cardiometabolic category, Taltz in immunology, and Verzenio in oncology are the future of Eli Lilly’s growth. While the aforementioned are the safer bets, the company has a handful of other drugs that could hold blockbuster potential.
- Strategic Acquisitions: The acquisition of Morphic, with its promising drug candidate MORF-057, is a testament to Lilly’s strategic vision. This drug, if successful in late-stage trials, could become a major success in the treatment of inflammatory bowel disease (IBD). Lilly’s focus on acquiring mid-sized companies (13 since 2020) with promising pipelines has bolstered its own research and development efforts, positioning it well for future growth.
- Operational Efficiency: With a sound balance sheet, Eli Lilly should continue to improve operational efficiency and manage costs to have net income growth rates above revenue growth.
Eli Lilly (LLY) Stock Price Prediction in 2025
The current Wall Street consensus 1-year price target of Eli Lilly stock is $1030.00, which is 10.75% higher than today’s price of $930.00. Of the 26 analysts covering Eli Lilly stock, the current rating is 1.67 or “Outperform” with 1-year price targets as high as $1,100 and as low as $540.00.
24/7 Wall Street sets its 1-year price target at $1,040. Taking a look at the sum of its parts, we see Eli Lilly’s vertices valued as follows:
| Endocrinology | $735/ share |
| Oncology | $122/ Share |
| Cardiovascular | $4/ Share |
| Neuroscience | $16/ Share |
| Immunology | $38/ Share |
| Others and Pipeline | $110/ Share |
| Cash | $17/ Share |
Eli Lilly’s Share Price Estimates 2025-2030
Valuing Eli Lilly’s stock price for the coming years, we will take a look at expected revenue and net income and give our best estimate of the market value of the company by assigning a price-to-earnings multiple.
| Revenue | Net Income | EPS | |
| 2025 | $52.8 | $17.29 | 19.11 |
| 2026 | $62.5 | $22.49 | 25.03 |
| 2027 | $70.87 | $27.12 | 30.39 |
| 2028 | $80.68 | $32.2 | 25.97 |
| 2029 | $87.99 | $36.45 | 40.58 |
| 2030 | $96.67 | $41.12 | 46.29 |
*Revenue and net income reported in billions
How Eli Lilly’s Next 5 Years Could Play Out
We expect Eli Lilly’s P/E ratio in 2025 to be 60 with an EPS of $19.11, resulting in a price target of $1140.00 This prediction is based on strong revenue growth of 18.37% to $52.80 billion and net income expansion to $17.29 billion, continuing the upward trajectory from previous years.
For 2026, we anticipate a P/E ratio of 50 with an EPS of $25.03, leading to a price target of $1250.00. This reflects significant revenue growth of 18.37% to $62.50 billion and an increase in net income to $22.49 billion, driving higher earnings per share.
Heading into 2027, we project the P/E ratio to remain at 50, with EPS increasing to $30.39. This results in a price target of $1520.00. Continued revenue growth of 13.39% to $70.87 billion and net income expansion to $27.12 billion justifies this substantial increase in stock price.
With an EPS of $25.97 and a P/E ratio of 50 in 2028, we forecast the stock price to be $1300.00. A slight dip in EPS growth is expected, but sustained strong performance in net income to $32.20 billion and revenue growth of 13.84% to $80.68 billion keeps the stock highly valued.
By 2029, we estimate Eli Lilly’s EPS to rise to $40.58, with the P/E ratio adjusting to 40. This gives us a price target of $1623.00. The continuous revenue growth of 9.06% to $87.99 billion and net income expansion to $36.45 billion supports this higher valuation.
Eli Lilly Stocks Price Target for 2030
Price Target: $1850.00
Upside: 98.92%
By 2030, we estimate Eli Lilly’s EPS to rise to $46.29, with the P/E ratio adjusting to 40. This gives us a price target of $1850.00. The continuous revenue growth of 9.86% to $96.67 billion and net income expansion to $41.12 billion supports this higher valuation.
| Year | Price Target | % Change From Current Price |
|---|---|---|
| 2025 | $1140.00 | Upside of 22.58% |
| 2026 | $1250.00 | Upside of 34.41% |
| 2027 | $1520.00 | Upside of 63.44% |
| 2028 | $1300.00 | Upside of 39.78% |
| 2029 | $1623.00 | Upside of 74.52% |
| 2030 | $180.00 | Upside of 98.92% |
Get Ready To Retire (Sponsored)
Start by taking a quick retirement quiz from SmartAsset that will match you with up to 3 financial advisors that serve your area and beyond in 5 minutes, or less.
Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests.
Here’s how it works:
1. Answer SmartAsset advisor match quiz
2. Review your pre-screened matches at your leisure. Check out the advisors’ profiles.
3. Speak with advisors at no cost to you. Have an introductory call on the phone or introduction in person and choose whom to work with in the future
Get started right here.
The post Eli Lilly (LLY) Stock Price Prediction and Forecast 2025-2030 appeared first on 24/7 Wall St..